A detailed history of Opaleye Management Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 218,000 shares of NTLA stock, worth $4.3 Million. This represents 1.25% of its overall portfolio holdings.

Number of Shares
218,000
Previous 255,000 14.51%
Holding current value
$4.3 Million
Previous $7.02 Million 30.46%
% of portfolio
1.25%
Previous 1.71%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$20.02 - $27.22 $740,740 - $1.01 Million
-37,000 Reduced 14.51%
218,000 $4.88 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $3.72 Million - $5.12 Million
156,000 Added 157.58%
255,000 $7.02 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $2.29 Million - $3.2 Million
99,000 New
99,000 $3.02 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $4.15 Million - $5.52 Million
120,000 New
120,000 $4.89 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.5B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.